Clinical Trial Update: Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating whether pioglitazone can reduce sympathetic overactivity in patients with chronic kidney disease, and the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: The University of Texas at Arlington | Conditions: Chronic Kidney Diseases | Phase 4 | Status: RECRUITING